header advert
Results 1 - 2 of 2
Results per page:
Orthopaedic Proceedings
Vol. 105-B, Issue SUPP_17 | Pages 49 - 49
24 Nov 2023
Azamgarhi T Perez-Sanchez C Warren S Scobie A Karunaharan N Houghton R Hassan S Kershaw H Sendi P Saeed K
Full Access

Aim

Dalbavancin is a lipoglycopeptide with a half-life of 14 days (range 6.1 to 18.4), significantly longer than other antimicrobials, which avoids the need for daily antibiotic dosing. This multi-centre observational study aims to describe the use of dalbavancin to facilitate discharge in treating bone and joint infections.

Method

All adult patients treated with dalbavancin from January 2017 to September 2022 in four UK bone infection units were included.

Data collected through a standardised data collection form included:

Clinical and microbiological characteristics.

Hospital length of stay.

Complications.

Patient suitability for hypothetical treatment options, such as Outpatient Parenteral

Antibiotic Team (OPAT)

Clinical outcome.

Treatment-related costs were calculated for dalbavancin and the preferred hypothetical treatment option that would have been administered for the same duration. The costs were subtracted to calculate the cost difference.

Clinical success was defined as the absence of definite failure in accordance with the OVIVA Trial protocol.


Orthopaedic Proceedings
Vol. 104-B, Issue SUPP_10 | Pages 51 - 51
1 Oct 2022
Azamgarhi T Scobie A Karunaharan N Mepham SO Mack D Vekaria K Crick K Chin SH Warren S
Full Access

Aim

There is a lack of data supporting the use of doxycycline as a single agent after removing infected orthopaedic metalwork. We evaluated the efficacy and safety of doxycycline compared with other single antibiotic regimens used at our specialist orthopaedic hospital.

Methods

A retrospective observational study including all adult patients diagnosed with an orthopaedic metalwork infection due to staphylococci. All patients were managed with the removal of metalwork, and multiple intraoperative samples were sent for culture, followed by the administration of at least four weeks of oral antibiotics. Antibiotic selection was on the recommendation of an infection consultant.

Infection outcome was assessed as the proportion of patients meeting the OVIVA Trial definition of definite failure at follow-up. The probability of definite failure for doxycycline and the alternatives group was estimated using the Kaplan-Meier survival method. All adverse drug reactions (ADR) during treatment were analysed.